U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H19ClO3
Molecular Weight 366.8382
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATOVAQUONE

SMILES

c1ccc2c(c1)C(=O)C(=C(C2=O)O)[C@@]3([H])CC[C@@]([H])(CC3)c4ccc(cc4)Cl

InChI

InChIKey=KUCQYCKVKVOKAY-CTYIDZIISA-N
InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-

HIDE SMILES / InChI

Molecular Formula C22H19ClO3
Molecular Weight 366.8382
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity UNSPECIFIED

Atovaquone is a chemical compound that belongs to the class of naphthoquinones; it is manufactured in the US in the liquid form, or oral suspension, under the brand name Mepron. Meron is used for the treatment or prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX. The mechanism of action against Pneumocystis jiroveci has not been fully elucidated. In Plasmodium species, the site of action appears to be the cytochrome bc1 complex (Complex III). Several metabolic enzymes are linked to the mitochondrial electron transport chain via ubiquinone. Inhibition of electron transport by atovaquone results in indirect inhibition of these enzymes. The ultimate metabolic effects of such blockade may include inhibition of nucleic acid and adenosine triphosphate (ATP) synthesis. Several laboratories, using different in vitro methodologies, have shown the IC50 (50% inhibitory concentration) of atovaquone against P. jiroveci to be 0.1 to 3.0 mcg/mL.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q08210
Gene ID: 3885966.0
Gene Symbol: NA
Target Organism: Plasmodium falciparum (isolate 3D7)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MEPRON

Approved Use

1.1 Prevention of Pneumocystis jiroveci Pneumonia. MEPRON® suspension is indicated for the prevention of Pneumocystis jiroveci pneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). 1.2 Treatment of Mild-to-Moderate Pneumocystis jiroveci Pneumonia MEPRON suspension is indicated for the acute oral treatment of mild-to-mod

Launch Date

7.2264961E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.8 μg/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
15.1 μg/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
15.1 μg/mL
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FED
15.3 μg/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FED
16.8 μg/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FED
24 μg/mL
750 mg 2 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
169 μg × h/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
280 μg × h/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
324 μg × h/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
801 μg × h/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
0.1%
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
0.1%
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
0.1%
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
0.1%
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FED
0.1%
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FED
0.1%
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FED
0.1%
750 mg 2 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATOVAQUONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources: Page: p.559
unhealthy
n = 6
Health Status: unhealthy
Condition: HIV inection
Population Size: 6
Sources: Page: p.559
31500 mg single, oral
Overdose
Dose: 31500 mg
Route: oral
Route: single
Dose: 31500 mg
Co-administed with::
dapsone
Sources: Page: p.16
unhealthy
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Sources: Page: p.16
Other AEs: Methemoglobinemia, Rash...
Other AEs:
Methemoglobinemia
Rash
Sources: Page: p.16
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 175
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 175
Sources: Page: p.12
Disc. AE: Rash, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Rash (grade 1-2, 6%)
Diarrhea (4%)
Nausea (3%)
Sources: Page: p.12
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 203
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 203
Sources: Page: p.12
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (4%)
Sources: Page: p.12
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.13
unhealthy
n = 203
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 203
Sources: Page: p.13
Disc. AE: Vomiting, ALT increased...
AEs leading to
discontinuation/dose reduction:
Vomiting (<1%)
ALT increased (2%)
Aspartate aminotransferase increase (2%)
Sources: Page: p.13
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.15
unhealthy
n = 73
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 73
Sources: Page: p.15
Disc. AE: Creatinine increased, Blood urea nitrogen increased...
AEs leading to
discontinuation/dose reduction:
Creatinine increased (1%)
Blood urea nitrogen increased (1%)
Amylase increased (1%)
Sources: Page: p.15
AEs

AEs

AESignificanceDosePopulation
Methemoglobinemia
31500 mg single, oral
Overdose
Dose: 31500 mg
Route: oral
Route: single
Dose: 31500 mg
Co-administed with::
dapsone
Sources: Page: p.16
unhealthy
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Sources: Page: p.16
Rash
31500 mg single, oral
Overdose
Dose: 31500 mg
Route: oral
Route: single
Dose: 31500 mg
Co-administed with::
dapsone
Sources: Page: p.16
unhealthy
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Sources: Page: p.16
Nausea 3%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 175
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 175
Sources: Page: p.12
Diarrhea 4%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 175
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 175
Sources: Page: p.12
Rash grade 1-2, 6%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 175
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 175
Sources: Page: p.12
Rash 4%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 203
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 203
Sources: Page: p.12
ALT increased 2%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.13
unhealthy
n = 203
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 203
Sources: Page: p.13
Aspartate aminotransferase increase 2%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.13
unhealthy
n = 203
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 203
Sources: Page: p.13
Vomiting <1%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.13
unhealthy
n = 203
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 203
Sources: Page: p.13
Amylase increased 1%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.15
unhealthy
n = 73
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 73
Sources: Page: p.15
Blood urea nitrogen increased 1%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.15
unhealthy
n = 73
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 73
Sources: Page: p.15
Creatinine increased 1%
Disc. AE
1500 mg 1 times / day multiple, oral
Recommended
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources: Page: p.15
unhealthy
n = 73
Health Status: unhealthy
Condition: Pneumocystis carinii pneumonia
Population Size: 73
Sources: Page: p.15
PubMed

PubMed

TitleDatePubMed
Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.
1990 Feb
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
1991 Feb
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.
1991 Jul
566C80, an antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients.
1991 Nov-Dec
In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
1992 Feb
Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate.
1993 Aug
The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
1993 Feb
Rifabutin is active in murine models of toxoplasmosis.
1994 Mar
Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model.
1994 Oct
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.
1994 Oct
Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
1995 Apr
Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.
1995 Dec
Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.
1995 Feb
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
1995 Nov 24
Acute severe autonomic insufficiency during pentamidine therapy.
1995 Oct
Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
1996
Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
1996 May
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.
1996 Sep
In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
1996 Sep
Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.
1996 Sep-Oct
Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.
1997 Feb
Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.
1997 Feb
Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis.
1997 Jan
Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
1997 Jan
Chronic infection with Toxoplasma gondii does not prevent acute disease or colonization of the brain with tissue cysts following reinfection with different strains of the parasite.
1997 Jun
Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.
1998 Apr
Plasmodium falciparum: the effects of atovaquone resistance on respiration.
2001 Aug
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
2001 Jun
Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
2002 Dec
Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.
2004 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Acute hepatitis and atovaquone/proguanil.
2005 Sep-Oct
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.
2008 Jan 28
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
2011 Apr
Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors.
2011 Dec 23
Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.
2011 Oct
Synthetic chromanol derivatives and their interaction with complex III in mitochondria from bovine, yeast, and Leishmania.
2011 Oct 17
Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug.
2012 Apr 15
New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
2012 Dec
Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.
2012 Dec 26
Characterization of Plasmodium liver stage inhibition by halofuginone.
2012 May
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.
2013 Dec 17
4(1H)-Quinolones with liver stage activity against Plasmodium berghei.
2013 Jan
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
2013 Jun 13
Quinolone-3-diarylethers: a new class of antimalarial drug.
2013 Mar 20
The antimalarial activities of methylene blue and the 1,4-naphthoquinone 3-[4-(trifluoromethyl)benzyl]-menadione are not due to inhibition of the mitochondrial electron transport chain.
2013 May
Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents.
2013 Nov
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
In vitro and in vivo combination of cepharanthine with anti-malarial drugs.
2014 Mar 12
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

Dosage for the Prevention of P. jiroveci Pneumonia: 1,500 mg (10 mL) once daily administered with food. Dosage for the Treatment of Mild-to-Moderate P. jiroveci Pneumonia The recommended oral dosage is 750 mg (5 mL) twice daily (total daily dose = 1,500 mg) administered with food for 21 days.
Route of Administration: Oral
IC50 of atovaquone against P. jiroveci to be 0.1 to 3.0 mcg/mL.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:47 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:47 UTC 2021
Record UNII
Y883P1Z2LT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATOVAQUONE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
2-(TRANS-4-(P-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHOQUINONE
Common Name English
ATOVAQUONE [MART.]
Common Name English
MEPRON
Brand Name English
NSC-759582
Code English
ATOVAQUONE [USP MONOGRAPH]
Common Name English
ATOVAQUONE [USAN]
Common Name English
ATOVAQUONE [USP-RS]
Common Name English
MALARONE COMPONENT ATOVAQUONE
Common Name English
ATOVAQUONE [VANDF]
Common Name English
ATOVAQUONE [ORANGE BOOK]
Common Name English
MALARONE PEDIATRIC COMPONENT ATOVAQUONE
Common Name English
1,4-NAPHTHALENEDIONE, 2-(4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-, TRANS-
Common Name English
ATOVAQUONE [INN]
Common Name English
ATOVAQUONE COMPONENT OF MALARONE PEDIATRIC
Common Name English
ATOVAQUONE [JAN]
Common Name English
ATOVAQUONE [EP MONOGRAPH]
Common Name English
566C
Code English
566C80
Code English
ATOVAQUONE [MI]
Common Name English
ATOVAQUONE [WHO-DD]
Common Name English
ATOVAQUONE COMPONENT OF MALARONE
Common Name English
ATOVAQUONE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C277
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
FDA ORPHAN DRUG 48890
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
FDA ORPHAN DRUG 66692
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
FDA ORPHAN DRUG 48990
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
NDF-RT N0000175482
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
WHO-ATC P01AX06
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
FDA ORPHAN DRUG 66792
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
LIVERTOX 73
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
NDF-RT N0000175485
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
Code System Code Type Description
WIKIPEDIA
ATOVAQUONE
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
RXCUI
60212
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY RxNorm
HSDB
7083
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
NCI_THESAURUS
C28838
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
MERCK INDEX
M2127
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB01117
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL1450
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
USP_CATALOG
1044651
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY USP-RS
INN
6914
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
LACTMED
Atovaquone
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
FDA UNII
Y883P1Z2LT
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
MESH
D053626
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
LACTMED
Atovaquone and Proquanil
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
CAS
95233-18-4
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
DRUG CENTRAL
258
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
EVMPD
SUB05602MIG
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
EPA CompTox
95233-18-4
Created by admin on Fri Jun 25 21:02:47 UTC 2021 , Edited by admin on Fri Jun 25 21:02:47 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
calculated on the anhydrous and organic solvent-free basis
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC